Table 1 Characteristics of the included randomized controlled trials
First author, year of publication | N. patients | Inclusion criteria | Follow-up (months) | Arm | Dose | Age, yrs | Female, n (%) | Radiotherapy, n (%) |
|---|---|---|---|---|---|---|---|---|
Kalay, 2006 [6] | 50 | Patients with malignancy and planned ANT therapy | 6 | Carvedilol | 12.5 mg, once daily | 46.8 ± 14 | 22 (88) | 0 |
Placebo | Corresponding dose | 49.0 ± 9.8 | 21 (84) | 0 | ||||
Georgakopoulos, 2010 [5] | 125 | Lymphoma patients | 31 | Metoprolol | 100 mg, daily target doses | 51.0 ± 18.0 | 20 (48) | 8 (19) |
Placebo | Corresponding dose | 49.1 ± 19.4 | 19 (47) | 9 (23) | ||||
Kaya, 2012 | 45 | Breast cancer patients planned anthracycline-based chemotherapy | 6 | Nebivolol | 5 mg, once daily | 51.4 ± 9.4 | 27 (100) | 7 (26) |
Placebo | Corresponding dose | 50.5 ± 11.1 | 18 (100) | 5 (28) | ||||
Bosch, 2013 [8] | 90 | Acute leukemia or patients with malignant hemopathies undergoing autologous hematopoietic stem cell transplantation (HSCT) and without LVSD | 6 | Carvedilol | 25 mg, twice daily | 49.7 ± 13.9 | 18 (40) | 12 (27) |
Placebo | Corresponding dose | 50.9 ± 13.2 | 21 (47) | 4 (9) | ||||
Liu, 2013 [13] | 40 | Patients with breast cancer and chemotherapy with FEC | 6 Chemotherapy Circle | Carvedilol | 5 mg, twice daily | 53 (39–68)a | 20 (100) | 0 |
Placebo | Corresponding dose | 54 (37–65)a | 20 (100) | 0 | ||||
Elitok, 2014 [14] | 80 | Patients with breast cancer and anticipated ANT therapy | 6 | Carvedilol | 12.5 mg, twice daily | 54.3 ± 9.3 | 40 (100) | 0 |
Placebo | Corresponding dose | 52.9 ± 11.2 | 40 (100) | 0 | ||||
Beheshti, 2016 [16] | 70 | Pathologically confirmed nonmetastatic breast cancer patients | 6 | Carvedilol | 6.25 mg, twice daily | 42.0 | 30 (100) | 0 |
Placebo | Corresponding dose | 39.9 | 40 (100) | 0 | ||||
Gulati, 2016 [12] | 130 | Women with early stage breast cancer who after breast cancer surgery were scheduled to initiate chemotherapy with FEC | 10 to 61 weeks | Candesartan + Metoprolol | 32 mg + 100 mg, once daily | 50.0 ± 8.9 | 30 (100) | 18 (60.0) |
Candesartan + Placebo | 32 mg + corresponding dose, once daily | 51.7 ± 10.7 | 32 (100) | 19 (59.4) | ||||
Metoprolol + Placebo | 100 mg + corresponding dose, once daily | 50.5 ± 9.1 | 32 (100) | 22 (68.8) | ||||
Placebo + Placebo. | Corresponding dose | 50.8 ± 9.2 | 32 (100) | 23 (71.9) | ||||
Jhorawat1, 2016 [15] | 54 | Patients diagnosed with lymphoreticular malignancy and planned for chemotherapy (CT) with regimen containing ANT | 6 | Carvedilol | 12.5 mg, once daily | 43.89 ± 15.66 | 4 (14.8) | 0 |
Placebo | Corresponding dose | 38.74 ± 18.36 | 9 (33.3) | 0 | ||||
Nabati, 2017 [17] | 91 | Women with newly diagnosed breast cancer treated with ANT therapy | 6 | Carvedilol | 6.125 mg, twice daily | 47.10 ± 12.17 | 46 (100) | 0 |
Placebo | Corresponding dose | 47.57 ± 8.75 | 45 (100) | 0 | ||||
Avila, 2018 [9] | 200 | Patients with HER2-negative breast cancer tumor status and therapy that included anthracycline, cyclophosphamide | 6 | Carvedilol | 25 mg, twice a day | 50.80 ± 10.10 | 96 (100) | 0 |
Placebo | Corresponding dose | 52.9 ± 9.05 | 96 (100) | 0 |